Devyser Diagnostics ABFRA:OL0 77 PB Ratio is 3.81 as of Jun. 25, 2026, which is at its 10-year median of 3.81. GuruFocus rates FRA:OL0 with a GF Score™ of 77/100 and a GF Value™ of €14.06 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Devyser Diagnostics AB ranks worse than 74.11% on this metric.
The historical rank and industry rank for Devyser Diagnostics AB's PB Ratio or its related term are showing as below:
FRA:OL0'
s PB Ratio Range Over the Past 10 Years
Min: 2.24 Med: 3.81 Max: 7.71
Current: 4.04
During the past 9 years, Devyser Diagnostics AB's highest PB Ratio was 7.71. The lowest was 2.24. And the median was 3.81.
FRA:OL0's PB Ratio is ranked worse than 74.11% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs FRA:OL0: 4.04
During the past 12 months, Devyser Diagnostics AB's average Book Value Per Share Growth Rate was 7.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 30.90% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Devyser Diagnostics AB was 118.80% per year. The lowest was -8.40% per year. And the median was 51.90% per year.
Back to Basics: PB Ratio
Devyser Diagnostics AB (FRA:OL0) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Devyser Diagnostics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devyser Diagnostics AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Devyser Diagnostics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Devyser Diagnostics AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Devyser Diagnostics AB (FRA:OL0) has a PB Ratio of 3.81 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Devyser Diagnostics AB and its competitors. This is near median its historical median of 3.81. Over the past decade, Devyser Diagnostics AB's PB Ratio has ranged from 2.24 to 7.71. According to the industry distribution chart, Devyser Diagnostics AB ranks #584 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 74.1%.
Is Devyser Diagnostics AB's PB Ratio too high?
Devyser Diagnostics AB's current PB Ratio of 3.81 is near median its 10-year median of 3.81. Over the past 10 years, this metric has ranged from a low of 2.24 to a high of 7.71. The Medical Devices & Instruments industry median PB Ratio is 2.05. Devyser Diagnostics AB's value of 3.81 is 86.3% above this industry median. Based on the distribution chart, Devyser Diagnostics AB ranks #584 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Devyser Diagnostics AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Devyser Diagnostics AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Devyser Diagnostics AB ranks #584 out of 788 companies for PB Ratio. This places Devyser Diagnostics AB in the lower half of its industry. The industry median PB Ratio is 2.05. Devyser Diagnostics AB's value of 3.81 is 86.3% above this benchmark. Historically, Devyser Diagnostics AB's own PB Ratio has ranged from 2.24 to 7.71 over the past decade. While the company's 10-year median is 3.81 vs. the industry median of 2.05, Devyser Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devyser Diagnostics AB's current PB Ratio of 3.81 is 86.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Devyser Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devyser Diagnostics AB's current PB Ratio is 3.81, which is near median its own 10-year median of 3.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devyser Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, Devyser Diagnostics AB (FRA:OL0) is currently considered Significantly Undervalued. The stock's GF Value™ is €14.06, compared to a current price of €7.59 — trading 46% below its estimated fair value. The current PB Ratio is 3.81, which is near median its 10-year median of 3.81 and 86.3% above the Medical Devices & Instruments industry median of 2.05. Devyser Diagnostics AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Devyser Diagnostics AB (FRA:OL0), the current PB Ratio is 3.81 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devyser Diagnostics AB (FRA:OL0) Overvalued in 2026?
Based on GuruFocus' analysis, Devyser Diagnostics AB stock appears to be undervalued.
The current stock price of €7.59 is trading 46% below its estimated GF Value™ of €14.06.
GuruFocus considers Devyser Diagnostics AB to be Significantly Undervalued.
Key valuation signals for FRA:OL0:
PB Ratio: 3.81 (near median its 10-year median of 3.81)
GF Value™: €14.06 vs. price of €7.59 (46% below fair value)
Industry Position: 86.3% above the Medical Devices & Instruments median (#584 of 788)
No single metric tells the full story. See the FRA:OL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
77GF Score
Get the complete analysis for FRA:OL0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OL0 has been successfully added to your 
